Back to Search Start Over

Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases

Authors :
Oomen, Ilja
Rashid, Amara Nassar-Sheikh
Bouts, Antonia H. M.
Gouw, Samantha C.
Kuijpers, Taco W.
Rispens, Theo
de Vries, Annick
Wolbink, Gertjan
van den Berg, J. Merlijn
Schonenberg-Meinema, Dieneke
Graduate School
Paediatric Pulmonology
Paediatric Nephrology
Paediatric Haematology
Landsteiner Laboratory
Paediatric Infectious Diseases / Rheumatology / Immunology
AII - Infectious diseases
AII - Inflammatory diseases
ARD - Amsterdam Reproduction and Development
Rheumatology
Radiation Oncology
Source :
Clinical and experimental rheumatology, 39(5), 183-190. Clinical and Experimental Rheumatology S.A.S., Clinical and Experimental Rheumatology, 40(1), 183-190. Clinical and Experimental Rheumatology S.A.S., Clinical and Experimental Rheumatology, 39(5), 183-190. Clinical and Experimental Rheumatology S.A.S., Oomen, I, Rashid, A N-S, Bouts, A H M, Gouw, S C, Kuijpers, T W, Rispens, T, de Vries, A, Wolbink, G, van den Berg, J M & Schonenberg-Meinema, D 2021, ' Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases ', Clinical and Experimental Rheumatology, vol. 39, no. 5, pp. 183-190 . https://doi.org/10.55563/CLINEXPRHEUMATOL/FTIRA8
Publication Year :
2022

Abstract

Objective Rituximab (RTX) is a chimeric monoclonal CD20-antibody. Lack of efficacy has been suggested to be related to the presence of anti-drug antibodies (ADA). The aims of this study were to determine if ADA impact the pharmacokinetics (PK) and pharmacodynamics (PD) of RTX in children, whether the formation of ADA differs between various immune-mediated diseases and if it is related to the occurrence of infusion-related reactions (IRR). Methods All children 8 AU/ml. Results Of twenty-six children treated with RTX for various immune-mediated diseases, six patients were ADA-positive (23.1%). In all ADA-positive patients, RTX concentrations were undetectable in contrast to ADA-negative patients (median RTX concentration 3.1 μg/ml; IQR 0.57-12.0; p

Subjects

Subjects :
B-Lymphocytes
congenital, hereditary, and neonatal diseases and abnormalities
Immunology
Antibodies, Monoclonal
nutritional and metabolic diseases
hemic and immune systems
Antigens, CD20
enzymes and coenzymes (carbohydrates)
Treatment Outcome
Pharmacodynamics
Rheumatology
immune system diseases
Humans
Immunology and Allergy
Pharmacokinetics
Child
Rituximab
Retrospective Studies

Details

Language :
English
ISSN :
0392856X
Volume :
40
Issue :
1
Database :
OpenAIRE
Journal :
Clinical and Experimental Rheumatology
Accession number :
edsair.doi.dedup.....2d48e54751e7a44473cf54eed2e357dd

Tools

Authors Abstract Subjects Details